Pipeline

Celsion’s extensive oncology pipeline represents a comprehensive, integrated portfolio of targeted therapeutic agents, encompassing chemotherapy, immunotherapy, and RNA therapy.

Our Technologies

ThermoDox®, Celsion’s lead product candidate, incorporates lysolipid thermally sensitive liposomes (LTSLs), a unique liposomal technology that allows for the triggered release of a drug payload through low temperature (just above body temperature) heat activation.

TheraPlas™ is a versatile technology platform for the delivery of DNA and messenger RNA (mRNA) therapeutics via synthetic non-viral carriers and is uniquely capable of providing cell transfection capability for double-stranded DNA plasmids and large therapeutic RNA segments such as mRNA.

TheraSilence™ is a versatile technology platform focused on delivering synthetically generated small inhibitory RNAs (siRNAs), microRNAs, microRNA mimics, and related molecules that can regulate protein expression by exploiting endogenous cell mechanisms.

Welcome

Celsion is a biopharmaceutical company dedicated to the research and development of innovative, targeted therapies that address unmet medical needs in oncology. With the recent acquisition of EGEN, Inc., Celsion has become a fully integrated company with an extensive, complementary, multi-phase clinical pipeline; platform technologies for the discovery of novel, nucleic acid-based immunotherapies and other anti-cancer DNA/RNA therapies; and expertise from bench to bedside. 

News & Events